Safety and Effectiveness of the Orsiro Mission 48-mm Sirolimus Eluting Coronary Stent System in Subjects With Coronary Artery Lesions

A trial with no phase registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 150 participants.

Also called NCT06779630

  • Study
  • In this atlas

Overview

Design
Interventional study; allocation not applicable; no masking; primary purpose treatment
Phase
Not applicable
Enrolled
  • 150 participants (planned count) (from the registry)
Sponsor
  • Teleflex Registry lists this organization as the lead sponsor
Registry
  • NCT NCT06779630
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United States, Austria, France, Germany, Poland, Switzerland (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT06779630. Allocation not applicable; no masking; primary purpose treatment. Start 2025-07-18 (actual); primary completion 2027-09 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Safety and Effectiveness of the Orsiro Mission 48-mm Sirolimus Eluting Coronary Stent System in Subjects With Coronary Artery Lesions
Acronym
BIOFLOW-48
Intervention (Device)
Orsiro Mission 48-mm Sirolimus-Eluting Coronary Stent System
Lead sponsor
Teleflex (class: industry)
Collaborator
BIOTRONIK AG (A Teleflex Company) (class: not stated)

Record details

Record id
cardio:ct-nct06779630
Content hash
733b44fc7ca416cf3c9c48269b09c9ad6efb7b133909a8a75f97b6b2244ba66f